Onco Wiki / Indication

Cholangiocarcinoma (bile duct cancer) · Gemcitabine + cisplatin (advanced biliary tract cancer, 1L — ABC-02)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Trackstandard
Linked regimenREG-GEMCITABINE-CISPLATIN-CHOLANGIO
IDIND-CHOLANGIO-ADVANCED-GEM-CIS
TypeIndication
Statuspending_clinical_signoff
DiseasesDIS-CHOLANGIOCARCINOMA
SourcesSRC-NCCN-CNS-2025

Notes

STUB scaffold. Auto-generated minimal indication so engine can route end-to-end. Pending Clinical Co-Lead review per CHARTER §6.1 dev-mode signoff exemption. Status as of 2026-05-08: legacy / IO-contraindicated fallback. Preferred 1L indications for IO-eligible patients are IND-CHOLANGIO-METASTATIC-1L-DURVA-CHEMO (TOPAZ-1) and IND-CHOLANGIO-METASTATIC-1L-PEMBRO-CHEMO (KEYNOTE-966).

Used By

Algorithms

Indication